Biocept Inc. buy stratec
Start price
26.03.19
/
50%
€300.36
Target price
04.11.21
€811.80
Performance (%)
-65.44%
End price
05.11.21
€103.80
Summary
This prediction ended on 05.11.21 with a price of €103.80. Massive losses of -65.44% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Biocept Inc. | - | - | - | - |
| iShares Core DAX® | 0,99 % | 8,31 % | 7,03 % | 49,79 % |
| iShares Nasdaq 100 | 2,07 % | 16,77 % | 35,95 % | 96,63 % |
| iShares Nikkei 225® | 2,27 % | 15,61 % | 46,57 % | 69,05 % |
| iShares S&P 500 | 1,04 % | 11,08 % | 26,46 % | 68,09 % |
Comments by stratec for this prediction
In the thread Biocept Inc. diskutieren
stratec stimmt dem Sentiment von 'Buy' zu
Biocept’s Target Selector is a liquid biopsy platform which, in addition to providing actionable data based on circulating tumor DNA (ctDNA) analysis, incorporates circulating tumor cell (NYSE:CTC) analysis which differentiates the company in an increasingly ‘crowded’ liquid biopsy space.”
In the thread Trading Biocept Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten